Takeda and Seattle Genetics report positive results from Adcetris
Seattle Genetics and Japan’s largest drugmaker Takeda Pharmaceutical have reported positive results from the Phase III trials of Adcetris (brentuximab vedotin) for consolidation in post-transplant Hodgkin’s lymphoma.
The results were submitted to the American Society of Hematology for their annual meeting. The data showed that patients with Hodgkin’s lymphoma who received Adcetris as consolidation therapy immediately following an autologous stem cell transplantation lived significantly longer without the disease progressing compared to patients in the placebo arm.
The study compared the use of single-agent Adcetris to placebo in 329 patients with Hodgkin’s lymphoma at risk of relapse. Adcetris is an antibody-drug conjugate directed to CD30, a defining marker of classical Hodgkin’s lymphoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze